To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Milestone Strategic Agreement to Commercialise Australian Biotech Innovation
09-12-2003: Benitec Limited, Commonwealth Scientific and Industrial Research Organisation (CSIRO), and the Queensland Department of Primary Industries (Queensland DPI), have today announced a strategic agreement that will accelerate Australia's lead in the global commercialisation of DNA Directed RNA interference, a breakthrough gene silencing technology. Called ddRNAi, this technology is able to be utilised in most bio-research institutes, biotech and pharmaceutical companies worldwide. This field of research is rapidly expanding, potentially generating market opportunities worth billions of dollars.
Invented in Australia , ddRNAi is the most advanced technology for inducing RNA interference (RNAi), a natural cellular mechanism that silences or selectively negates the effect of targeted genes within any cell of any multi-cellular organism.
Applications for this technology may include the treatment of human disease such as cancer, auto-immune disorders and viral infections by shutting down or suppressing genes that cause these diseases . Equally important applications exist in the fields of plant improvement and animal healthcare.
This agreement fully resolves the dispute between Benitec, CSIRO and Queensland DPI. All parties retain research rights in their fields of interest . John McKinley, Chairman and Chief Executive Officer of Benitec said "This deal provides clear and certain commercialisation pathways for this technology."
Benitec will focus on commercialising ddRNAi for "human applications" including research models used in functional genomics. CSIRO will focus on commercialising "non-human applications", including plants, animals and insects. Queensland DPI will continue its ddRNAi research and will benefit from access to both Benitec and CSIRO's global commercialisation pathways.
CSIRO scientists have a distinguished track record in gene silencing, having pioneered technologies including selective DNA-methylation technologies. CSIRO successfully demonstrated DNA delivered RNA interference in plants and continues to make significant investments in pioneering research in this field.
Mehrdad Baghai, Executive Director of Business Development and Commercialisation for CSIRO said "This agreement exemplifies CSIRO's new "can do" approach to partnering with industry to unlock the value of our science. This gene silencing technology will be a key platform for Australian research in Life Sciences over the next decade" said Baghai.
Queensland DPI's Director of Biotechnology Research Dr Peter Young said the landmark agreement is a shining example of the value of partnerships between public and private entities in Australia - allowing cutting edge research to achieve its full commercial potential.
"DPI's scientists will continue to apply ddRNAi technology to seek improvements in agricultural production systems, with unparalleled access to the commercialisation routes of our two partners," Dr Young said.
"This agreement gives Benitec the freedom to pursue its strategic focus on the clinical development and commercialisation of human therapeutics while providing the opportunity to share in revenues CSIRO generates from other applications" said McKinley.
Benitec and CSIRO will share revenues generated from the commercial applications of ddRNAi, each party retaining the majority of revenue generated from its respective area. This agreement will unlock the enormous value of the ddRNAi intellectual property by accelerating the parallel development of commercial applications in both the human and non-human fields.
This agreement harnesses the extensive R&D capabilities of CSIRO, Queensland DPI and Benitec and enables Australian researchers to take the lead in the development and commercialisation of ddRNAi.
About ddRNAi Technology
DNA directed RNA interference (ddRNAi) is a method of inducing RNA interference (RNAi). RNAi is a natural cellular mechanism that selectively negates the effect of any gene by destroying messenger RNA (mRNA), the courier that delivers instructions from a gene to manufacture a protein. Suppression of protein synthesis offers a revolutionary new approach to controlling many diseases. RNAi interrupts protein synthesis by selectively destroying mRNA, "knocking down" or "silencing" the targeted gene.
The RNAi process is triggered by double-stranded RNA, where one strand is identical to the target mRNA sequence. ddRNAi technology involves inserting a DNA construct into a cell to produce the double-stranded RNA, resulting in the destruction of the target mRNA and silencing the expression of the target gene.
The ddRNAi approach has several advantages when compared with alternative gene silencing technologies under development, such as antisense RNA and siRNA. These advantages include lower cost and ease of preparation, more versatile delivery options, the ability to silence genes in whole organisms (transgenic ddRNAi) and the ability to control the expression and timing of gene silencing.
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Fighting listeria and other food-borne illnesses with nanobiotechnology
- 3Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Using human brain cells to make mice smarter
- 6Vivacta Initiates Development of Point of Care Test for Vitamin D
- 7A light switch inside the brain
- 8Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 9New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Carl Zeiss Meditec improves its results in first six months of financial yea ...
- Evonik selects OPX Biotechnologies for joint development of bio-based chemicals
- Frost & Sullivan commends Merck Serono for its excellence in product differe ...
- SYGNIS reports results for the first quarter of 2013
- ZEISS presents half-year financial figures